Abstract
Comparing patients treated after myocardial infarction with amiodarone or with placebo, we found a significant rate-dependent prolongation of TpTe interval in patients who received amiodarone. Patients who had arrhythmic death had significantly longer TpTe intervals than others on placebo but not on amiodarone. Assuming that TpTe reflects transmural repolarization heterogeneity, our findings suggest that heterogeneity and arrhythmic risk are increased by amiodarone. This contradicts the finding of decreased transmural repolarization heterogeneity by amiodarone and the appreciated antiarrhythmic efficacy of this drug.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Amiodarone / administration & dosage
-
Amiodarone / adverse effects*
-
Amiodarone / therapeutic use*
-
Anti-Arrhythmia Agents / administration & dosage
-
Anti-Arrhythmia Agents / adverse effects*
-
Anti-Arrhythmia Agents / therapeutic use*
-
Dose-Response Relationship, Drug
-
Electrocardiography, Ambulatory
-
Female
-
Heart Conduction System / drug effects
-
Heart Conduction System / physiopathology
-
Humans
-
Long QT Syndrome / chemically induced*
-
Long QT Syndrome / mortality
-
Long QT Syndrome / physiopathology*
-
Male
-
Middle Aged
-
Myocardial Infarction / drug therapy*
-
Myocardial Infarction / mortality
-
Myocardial Infarction / physiopathology*
-
Randomized Controlled Trials as Topic
-
Retrospective Studies
-
Severity of Illness Index
-
Survival Rate
Substances
-
Anti-Arrhythmia Agents
-
Amiodarone